nodes	percent_of_prediction	percent_of_DWPC	metapath
Trifluoperazine—XDH—Carboplatin—testicular cancer	0.214	0.319	CbGbCtD
Trifluoperazine—XDH—Cisplatin—testicular cancer	0.182	0.273	CbGbCtD
Trifluoperazine—XDH—Doxorubicin—testicular cancer	0.122	0.183	CbGbCtD
Trifluoperazine—ABCB1—Dactinomycin—testicular cancer	0.0362	0.0541	CbGbCtD
Trifluoperazine—CYP1A2—Etoposide—testicular cancer	0.0234	0.0349	CbGbCtD
Trifluoperazine—ABCB1—Vinblastine—testicular cancer	0.0227	0.0339	CbGbCtD
Trifluoperazine—ABCB1—Cisplatin—testicular cancer	0.0208	0.0311	CbGbCtD
Trifluoperazine—ABCB1—Etoposide—testicular cancer	0.0204	0.0305	CbGbCtD
Trifluoperazine—ABCB1—Doxorubicin—testicular cancer	0.0139	0.0208	CbGbCtD
Trifluoperazine—ABCB1—Methotrexate—testicular cancer	0.0135	0.0202	CbGbCtD
Trifluoperazine—CALM2—semen—testicular cancer	0.00963	0.0841	CbGeAlD
Trifluoperazine—CALM1—semen—testicular cancer	0.00958	0.0837	CbGeAlD
Trifluoperazine—S100A4—embryo—testicular cancer	0.00755	0.0659	CbGeAlD
Trifluoperazine—S100A4—seminal vesicle—testicular cancer	0.00709	0.0619	CbGeAlD
Trifluoperazine—HTR2A—vein—testicular cancer	0.00696	0.0608	CbGeAlD
Trifluoperazine—EBPL—female gonad—testicular cancer	0.00527	0.0461	CbGeAlD
Trifluoperazine—EBPL—testis—testicular cancer	0.00468	0.0408	CbGeAlD
Trifluoperazine—CALY—testis—testicular cancer	0.00428	0.0374	CbGeAlD
Trifluoperazine—S100A4—female gonad—testicular cancer	0.00416	0.0364	CbGeAlD
Trifluoperazine—S100A4—testis—testicular cancer	0.00369	0.0322	CbGeAlD
Trifluoperazine—EBPL—lymph node—testicular cancer	0.00339	0.0296	CbGeAlD
Trifluoperazine—TNNC1—testis—testicular cancer	0.00311	0.0271	CbGeAlD
Trifluoperazine—CALY—lymph node—testicular cancer	0.0031	0.0271	CbGeAlD
Trifluoperazine—S100A4—lymph node—testicular cancer	0.00268	0.0234	CbGeAlD
Trifluoperazine—CALM3—seminal vesicle—testicular cancer	0.0026	0.0227	CbGeAlD
Trifluoperazine—SIGMAR1—seminal vesicle—testicular cancer	0.00232	0.0203	CbGeAlD
Trifluoperazine—TNNC1—lymph node—testicular cancer	0.00225	0.0197	CbGeAlD
Trifluoperazine—CALM2—embryo—testicular cancer	0.00217	0.019	CbGeAlD
Trifluoperazine—CALM1—embryo—testicular cancer	0.00216	0.0189	CbGeAlD
Trifluoperazine—CALM2—seminal vesicle—testicular cancer	0.00204	0.0178	CbGeAlD
Trifluoperazine—CALM3—female gonad—testicular cancer	0.00153	0.0133	CbGeAlD
Trifluoperazine—CALM2—gonad—testicular cancer	0.00147	0.0129	CbGeAlD
Trifluoperazine—CALM1—gonad—testicular cancer	0.00147	0.0128	CbGeAlD
Trifluoperazine—SIGMAR1—female gonad—testicular cancer	0.00136	0.0119	CbGeAlD
Trifluoperazine—CALM3—testis—testicular cancer	0.00135	0.0118	CbGeAlD
Trifluoperazine—HTR2A—embryo—testicular cancer	0.00132	0.0115	CbGeAlD
Trifluoperazine—SIGMAR1—testis—testicular cancer	0.00121	0.0106	CbGeAlD
Trifluoperazine—CALM2—female gonad—testicular cancer	0.0012	0.0105	CbGeAlD
Trifluoperazine—CALM1—female gonad—testicular cancer	0.00119	0.0104	CbGeAlD
Trifluoperazine—CALM2—testis—testicular cancer	0.00106	0.00928	CbGeAlD
Trifluoperazine—CALM1—testis—testicular cancer	0.00106	0.00924	CbGeAlD
Trifluoperazine—CALM3—lymph node—testicular cancer	0.000981	0.00857	CbGeAlD
Trifluoperazine—DRD2—testis—testicular cancer	0.000977	0.00853	CbGeAlD
Trifluoperazine—HTR2A—gonad—testicular cancer	0.000894	0.00781	CbGeAlD
Trifluoperazine—SIGMAR1—lymph node—testicular cancer	0.000877	0.00766	CbGeAlD
Trifluoperazine—HRH1—female gonad—testicular cancer	0.00087	0.0076	CbGeAlD
Trifluoperazine—ABCB1—embryo—testicular cancer	0.000863	0.00754	CbGeAlD
Trifluoperazine—ABCB1—seminal vesicle—testicular cancer	0.000811	0.00708	CbGeAlD
Trifluoperazine—HRH1—testis—testicular cancer	0.000772	0.00674	CbGeAlD
Trifluoperazine—CALM2—lymph node—testicular cancer	0.000771	0.00673	CbGeAlD
Trifluoperazine—CALM1—lymph node—testicular cancer	0.000767	0.0067	CbGeAlD
Trifluoperazine—HTR2A—testis—testicular cancer	0.000645	0.00563	CbGeAlD
Trifluoperazine—Anorexia—Vinblastine—testicular cancer	0.00063	0.00303	CcSEcCtD
Trifluoperazine—Dyskinesia—Epirubicin—testicular cancer	0.000629	0.00303	CcSEcCtD
Trifluoperazine—Pancytopenia—Etoposide—testicular cancer	0.000629	0.00302	CcSEcCtD
Trifluoperazine—Decreased appetite—Chlorambucil—testicular cancer	0.000626	0.00301	CcSEcCtD
Trifluoperazine—Amenorrhoea—Doxorubicin—testicular cancer	0.000623	0.003	CcSEcCtD
Trifluoperazine—Fatigue—Chlorambucil—testicular cancer	0.000621	0.00299	CcSEcCtD
Trifluoperazine—Leukopenia—Bleomycin—testicular cancer	0.000612	0.00294	CcSEcCtD
Trifluoperazine—Gait disturbance—Epirubicin—testicular cancer	0.000606	0.00292	CcSEcCtD
Trifluoperazine—Cough—Bleomycin—testicular cancer	0.000596	0.00287	CcSEcCtD
Trifluoperazine—Aplastic anaemia—Methotrexate—testicular cancer	0.000593	0.00285	CcSEcCtD
Trifluoperazine—Hepatocellular injury—Epirubicin—testicular cancer	0.000592	0.00285	CcSEcCtD
Trifluoperazine—ABCB1—gonad—testicular cancer	0.000586	0.00512	CbGeAlD
Trifluoperazine—Erythema—Ifosfamide—testicular cancer	0.000584	0.00281	CcSEcCtD
Trifluoperazine—Dyskinesia—Doxorubicin—testicular cancer	0.000582	0.0028	CcSEcCtD
Trifluoperazine—Jaundice—Etoposide—testicular cancer	0.000575	0.00277	CcSEcCtD
Trifluoperazine—Decreased appetite—Vinblastine—testicular cancer	0.000574	0.00276	CcSEcCtD
Trifluoperazine—Urticaria—Chlorambucil—testicular cancer	0.000573	0.00275	CcSEcCtD
Trifluoperazine—Leukopenia—Dactinomycin—testicular cancer	0.000571	0.00274	CcSEcCtD
Trifluoperazine—Body temperature increased—Chlorambucil—testicular cancer	0.00057	0.00274	CcSEcCtD
Trifluoperazine—Gynaecomastia—Methotrexate—testicular cancer	0.000566	0.00272	CcSEcCtD
Trifluoperazine—Constipation—Vinblastine—testicular cancer	0.000565	0.00272	CcSEcCtD
Trifluoperazine—Gait disturbance—Doxorubicin—testicular cancer	0.000561	0.0027	CcSEcCtD
Trifluoperazine—HRH1—lymph node—testicular cancer	0.000559	0.00489	CbGeAlD
Trifluoperazine—Anaphylactic shock—Bleomycin—testicular cancer	0.000558	0.00268	CcSEcCtD
Trifluoperazine—Aplastic anaemia—Epirubicin—testicular cancer	0.000555	0.00267	CcSEcCtD
Trifluoperazine—Agranulocytosis—Etoposide—testicular cancer	0.000551	0.00265	CcSEcCtD
Trifluoperazine—Vision blurred—Ifosfamide—testicular cancer	0.00055	0.00265	CcSEcCtD
Trifluoperazine—Hepatocellular injury—Doxorubicin—testicular cancer	0.000547	0.00263	CcSEcCtD
Trifluoperazine—Agitation—Ifosfamide—testicular cancer	0.000537	0.00258	CcSEcCtD
Trifluoperazine—Angioedema—Ifosfamide—testicular cancer	0.000534	0.00257	CcSEcCtD
Trifluoperazine—Anorexia—Bleomycin—testicular cancer	0.000532	0.00256	CcSEcCtD
Trifluoperazine—Hypersensitivity—Chlorambucil—testicular cancer	0.000531	0.00255	CcSEcCtD
Trifluoperazine—Leukopenia—Ifosfamide—testicular cancer	0.000523	0.00251	CcSEcCtD
Trifluoperazine—Photosensitivity—Methotrexate—testicular cancer	0.000523	0.00251	CcSEcCtD
Trifluoperazine—Hypotension—Bleomycin—testicular cancer	0.000521	0.00251	CcSEcCtD
Trifluoperazine—Asthenia—Chlorambucil—testicular cancer	0.000517	0.00249	CcSEcCtD
Trifluoperazine—Aplastic anaemia—Doxorubicin—testicular cancer	0.000514	0.00247	CcSEcCtD
Trifluoperazine—Pruritus—Chlorambucil—testicular cancer	0.00051	0.00245	CcSEcCtD
Trifluoperazine—Cough—Ifosfamide—testicular cancer	0.00051	0.00245	CcSEcCtD
Trifluoperazine—Convulsion—Ifosfamide—testicular cancer	0.000506	0.00243	CcSEcCtD
Trifluoperazine—Erythema—Cisplatin—testicular cancer	0.000504	0.00242	CcSEcCtD
Trifluoperazine—Dyspnoea—Bleomycin—testicular cancer	0.000497	0.00239	CcSEcCtD
Trifluoperazine—Anorexia—Dactinomycin—testicular cancer	0.000496	0.00239	CcSEcCtD
Trifluoperazine—Photosensitivity—Epirubicin—testicular cancer	0.000489	0.00235	CcSEcCtD
Trifluoperazine—Hypersensitivity—Vinblastine—testicular cancer	0.000487	0.00234	CcSEcCtD
Trifluoperazine—Dermatitis exfoliative—Methotrexate—testicular cancer	0.000486	0.00234	CcSEcCtD
Trifluoperazine—Decreased appetite—Bleomycin—testicular cancer	0.000485	0.00233	CcSEcCtD
Trifluoperazine—Muscle spasms—Cisplatin—testicular cancer	0.000484	0.00233	CcSEcCtD
Trifluoperazine—Eczema—Epirubicin—testicular cancer	0.000478	0.0023	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Ifosfamide—testicular cancer	0.000477	0.00229	CcSEcCtD
Trifluoperazine—ABCB1—female gonad—testicular cancer	0.000476	0.00416	CbGeAlD
Trifluoperazine—Vision blurred—Cisplatin—testicular cancer	0.000475	0.00228	CcSEcCtD
Trifluoperazine—Anaphylactoid reaction—Methotrexate—testicular cancer	0.000474	0.00228	CcSEcCtD
Trifluoperazine—Asthenia—Vinblastine—testicular cancer	0.000474	0.00228	CcSEcCtD
Trifluoperazine—Tremor—Cisplatin—testicular cancer	0.000472	0.00227	CcSEcCtD
Trifluoperazine—Skin disorder—Ifosfamide—testicular cancer	0.000463	0.00223	CcSEcCtD
Trifluoperazine—Increased appetite—Epirubicin—testicular cancer	0.000457	0.0022	CcSEcCtD
Trifluoperazine—Dermatitis exfoliative—Epirubicin—testicular cancer	0.000455	0.00219	CcSEcCtD
Trifluoperazine—Anorexia—Ifosfamide—testicular cancer	0.000454	0.00219	CcSEcCtD
Trifluoperazine—Photosensitivity—Doxorubicin—testicular cancer	0.000452	0.00218	CcSEcCtD
Trifluoperazine—Decreased appetite—Dactinomycin—testicular cancer	0.000452	0.00218	CcSEcCtD
Trifluoperazine—Leukopenia—Cisplatin—testicular cancer	0.000451	0.00217	CcSEcCtD
Trifluoperazine—Fatigue—Dactinomycin—testicular cancer	0.000448	0.00216	CcSEcCtD
Trifluoperazine—Hypotension—Ifosfamide—testicular cancer	0.000445	0.00214	CcSEcCtD
Trifluoperazine—Anaphylactoid reaction—Epirubicin—testicular cancer	0.000444	0.00213	CcSEcCtD
Trifluoperazine—Muscle spasms—Etoposide—testicular cancer	0.000444	0.00213	CcSEcCtD
Trifluoperazine—Urticaria—Bleomycin—testicular cancer	0.000443	0.00213	CcSEcCtD
Trifluoperazine—Eczema—Doxorubicin—testicular cancer	0.000442	0.00213	CcSEcCtD
Trifluoperazine—Body temperature increased—Bleomycin—testicular cancer	0.000441	0.00212	CcSEcCtD
Trifluoperazine—Hypoglycaemia—Epirubicin—testicular cancer	0.00044	0.00212	CcSEcCtD
Trifluoperazine—Dizziness—Vinblastine—testicular cancer	0.000437	0.0021	CcSEcCtD
Trifluoperazine—Convulsion—Cisplatin—testicular cancer	0.000436	0.0021	CcSEcCtD
Trifluoperazine—Nausea—Chlorambucil—testicular cancer	0.000428	0.00206	CcSEcCtD
Trifluoperazine—Dyspnoea—Ifosfamide—testicular cancer	0.000425	0.00204	CcSEcCtD
Trifluoperazine—Somnolence—Ifosfamide—testicular cancer	0.000424	0.00204	CcSEcCtD
Trifluoperazine—Increased appetite—Doxorubicin—testicular cancer	0.000423	0.00203	CcSEcCtD
Trifluoperazine—ABCB1—testis—testicular cancer	0.000422	0.00369	CbGeAlD
Trifluoperazine—Dermatitis exfoliative—Doxorubicin—testicular cancer	0.000421	0.00203	CcSEcCtD
Trifluoperazine—Decreased appetite—Ifosfamide—testicular cancer	0.000414	0.00199	CcSEcCtD
Trifluoperazine—Headache—Vinblastine—testicular cancer	0.000414	0.00199	CcSEcCtD
Trifluoperazine—Leukopenia—Etoposide—testicular cancer	0.000413	0.00199	CcSEcCtD
Trifluoperazine—Body temperature increased—Dactinomycin—testicular cancer	0.000411	0.00198	CcSEcCtD
Trifluoperazine—Fatigue—Ifosfamide—testicular cancer	0.000411	0.00198	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Cisplatin—testicular cancer	0.000411	0.00198	CcSEcCtD
Trifluoperazine—Hypersensitivity—Bleomycin—testicular cancer	0.000411	0.00198	CcSEcCtD
Trifluoperazine—Anaphylactoid reaction—Doxorubicin—testicular cancer	0.000411	0.00197	CcSEcCtD
Trifluoperazine—Cardiac arrest—Epirubicin—testicular cancer	0.000408	0.00196	CcSEcCtD
Trifluoperazine—Constipation—Ifosfamide—testicular cancer	0.000408	0.00196	CcSEcCtD
Trifluoperazine—Hypoglycaemia—Doxorubicin—testicular cancer	0.000407	0.00196	CcSEcCtD
Trifluoperazine—Cough—Etoposide—testicular cancer	0.000403	0.00194	CcSEcCtD
Trifluoperazine—Asthenia—Bleomycin—testicular cancer	0.0004	0.00192	CcSEcCtD
Trifluoperazine—Convulsion—Etoposide—testicular cancer	0.0004	0.00192	CcSEcCtD
Trifluoperazine—Skin disorder—Cisplatin—testicular cancer	0.000399	0.00192	CcSEcCtD
Trifluoperazine—Asthma—Methotrexate—testicular cancer	0.000397	0.00191	CcSEcCtD
Trifluoperazine—Pruritus—Bleomycin—testicular cancer	0.000395	0.0019	CcSEcCtD
Trifluoperazine—Eosinophilia—Methotrexate—testicular cancer	0.000393	0.00189	CcSEcCtD
Trifluoperazine—Nausea—Vinblastine—testicular cancer	0.000392	0.00189	CcSEcCtD
Trifluoperazine—Anorexia—Cisplatin—testicular cancer	0.000392	0.00188	CcSEcCtD
Trifluoperazine—Hypotension—Cisplatin—testicular cancer	0.000384	0.00185	CcSEcCtD
Trifluoperazine—Hypersensitivity—Dactinomycin—testicular cancer	0.000383	0.00184	CcSEcCtD
Trifluoperazine—Muscular weakness—Epirubicin—testicular cancer	0.000379	0.00182	CcSEcCtD
Trifluoperazine—Urticaria—Ifosfamide—testicular cancer	0.000379	0.00182	CcSEcCtD
Trifluoperazine—Cardiac arrest—Doxorubicin—testicular cancer	0.000378	0.00182	CcSEcCtD
Trifluoperazine—Body temperature increased—Ifosfamide—testicular cancer	0.000377	0.00181	CcSEcCtD
Trifluoperazine—Pancytopenia—Methotrexate—testicular cancer	0.000377	0.00181	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Etoposide—testicular cancer	0.000377	0.00181	CcSEcCtD
Trifluoperazine—Asthenia—Dactinomycin—testicular cancer	0.000373	0.0018	CcSEcCtD
Trifluoperazine—Asthma—Epirubicin—testicular cancer	0.000371	0.00179	CcSEcCtD
Trifluoperazine—Dysphagia—Epirubicin—testicular cancer	0.000371	0.00179	CcSEcCtD
Trifluoperazine—Eosinophilia—Epirubicin—testicular cancer	0.000367	0.00177	CcSEcCtD
Trifluoperazine—Dyspnoea—Cisplatin—testicular cancer	0.000366	0.00176	CcSEcCtD
Trifluoperazine—Skin disorder—Etoposide—testicular cancer	0.000366	0.00176	CcSEcCtD
Trifluoperazine—Erectile dysfunction—Methotrexate—testicular cancer	0.000365	0.00176	CcSEcCtD
Trifluoperazine—Photosensitivity reaction—Methotrexate—testicular cancer	0.000362	0.00174	CcSEcCtD
Trifluoperazine—Anorexia—Etoposide—testicular cancer	0.000359	0.00173	CcSEcCtD
Trifluoperazine—Decreased appetite—Cisplatin—testicular cancer	0.000357	0.00172	CcSEcCtD
Trifluoperazine—Drowsiness—Methotrexate—testicular cancer	0.000354	0.0017	CcSEcCtD
Trifluoperazine—Pancytopenia—Epirubicin—testicular cancer	0.000352	0.0017	CcSEcCtD
Trifluoperazine—Hypotension—Etoposide—testicular cancer	0.000352	0.00169	CcSEcCtD
Trifluoperazine—Rash—Bleomycin—testicular cancer	0.000352	0.00169	CcSEcCtD
Trifluoperazine—Dermatitis—Bleomycin—testicular cancer	0.000351	0.00169	CcSEcCtD
Trifluoperazine—Hypersensitivity—Ifosfamide—testicular cancer	0.000351	0.00169	CcSEcCtD
Trifluoperazine—Muscular weakness—Doxorubicin—testicular cancer	0.00035	0.00169	CcSEcCtD
Trifluoperazine—Dysphagia—Doxorubicin—testicular cancer	0.000343	0.00165	CcSEcCtD
Trifluoperazine—Asthma—Doxorubicin—testicular cancer	0.000343	0.00165	CcSEcCtD
Trifluoperazine—Asthenia—Ifosfamide—testicular cancer	0.000342	0.00165	CcSEcCtD
Trifluoperazine—Eosinophilia—Doxorubicin—testicular cancer	0.00034	0.00164	CcSEcCtD
Trifluoperazine—Photosensitivity reaction—Epirubicin—testicular cancer	0.000339	0.00163	CcSEcCtD
Trifluoperazine—Weight increased—Epirubicin—testicular cancer	0.000338	0.00162	CcSEcCtD
Trifluoperazine—Pruritus—Ifosfamide—testicular cancer	0.000337	0.00162	CcSEcCtD
Trifluoperazine—Dyspnoea—Etoposide—testicular cancer	0.000336	0.00161	CcSEcCtD
Trifluoperazine—Hyperglycaemia—Epirubicin—testicular cancer	0.000335	0.00161	CcSEcCtD
Trifluoperazine—Somnolence—Etoposide—testicular cancer	0.000335	0.00161	CcSEcCtD
Trifluoperazine—Nausea—Bleomycin—testicular cancer	0.000331	0.00159	CcSEcCtD
Trifluoperazine—Drowsiness—Epirubicin—testicular cancer	0.000331	0.00159	CcSEcCtD
Trifluoperazine—Agranulocytosis—Methotrexate—testicular cancer	0.00033	0.00159	CcSEcCtD
Trifluoperazine—Rash—Dactinomycin—testicular cancer	0.000328	0.00158	CcSEcCtD
Trifluoperazine—Decreased appetite—Etoposide—testicular cancer	0.000327	0.00157	CcSEcCtD
Trifluoperazine—Pancytopenia—Doxorubicin—testicular cancer	0.000326	0.00157	CcSEcCtD
Trifluoperazine—Body temperature increased—Cisplatin—testicular cancer	0.000325	0.00156	CcSEcCtD
Trifluoperazine—Fatigue—Etoposide—testicular cancer	0.000325	0.00156	CcSEcCtD
Trifluoperazine—Jaundice—Epirubicin—testicular cancer	0.000323	0.00155	CcSEcCtD
Trifluoperazine—Constipation—Etoposide—testicular cancer	0.000322	0.00155	CcSEcCtD
Trifluoperazine—Dizziness—Ifosfamide—testicular cancer	0.000315	0.00152	CcSEcCtD
Trifluoperazine—Photosensitivity reaction—Doxorubicin—testicular cancer	0.000313	0.00151	CcSEcCtD
Trifluoperazine—Weight increased—Doxorubicin—testicular cancer	0.000313	0.0015	CcSEcCtD
Trifluoperazine—Hyperglycaemia—Doxorubicin—testicular cancer	0.00031	0.00149	CcSEcCtD
Trifluoperazine—Nausea—Dactinomycin—testicular cancer	0.000309	0.00149	CcSEcCtD
Trifluoperazine—Agranulocytosis—Epirubicin—testicular cancer	0.000309	0.00149	CcSEcCtD
Trifluoperazine—ABCB1—lymph node—testicular cancer	0.000306	0.00267	CbGeAlD
Trifluoperazine—Drowsiness—Doxorubicin—testicular cancer	0.000306	0.00147	CcSEcCtD
Trifluoperazine—Hypersensitivity—Cisplatin—testicular cancer	0.000303	0.00146	CcSEcCtD
Trifluoperazine—Rash—Ifosfamide—testicular cancer	0.000301	0.00145	CcSEcCtD
Trifluoperazine—Dermatitis—Ifosfamide—testicular cancer	0.0003	0.00144	CcSEcCtD
Trifluoperazine—Urticaria—Etoposide—testicular cancer	0.000299	0.00144	CcSEcCtD
Trifluoperazine—Jaundice—Doxorubicin—testicular cancer	0.000298	0.00144	CcSEcCtD
Trifluoperazine—Body temperature increased—Etoposide—testicular cancer	0.000298	0.00143	CcSEcCtD
Trifluoperazine—Asthenia—Cisplatin—testicular cancer	0.000295	0.00142	CcSEcCtD
Trifluoperazine—Oedema peripheral—Epirubicin—testicular cancer	0.000293	0.00141	CcSEcCtD
Trifluoperazine—Agranulocytosis—Doxorubicin—testicular cancer	0.000286	0.00137	CcSEcCtD
Trifluoperazine—Nausea—Ifosfamide—testicular cancer	0.000283	0.00136	CcSEcCtD
Trifluoperazine—Hypersensitivity—Etoposide—testicular cancer	0.000277	0.00133	CcSEcCtD
Trifluoperazine—Erythema—Methotrexate—testicular cancer	0.000276	0.00133	CcSEcCtD
Trifluoperazine—Oedema peripheral—Doxorubicin—testicular cancer	0.000271	0.0013	CcSEcCtD
Trifluoperazine—Asthenia—Etoposide—testicular cancer	0.00027	0.0013	CcSEcCtD
Trifluoperazine—Pruritus—Etoposide—testicular cancer	0.000266	0.00128	CcSEcCtD
Trifluoperazine—Vision blurred—Methotrexate—testicular cancer	0.00026	0.00125	CcSEcCtD
Trifluoperazine—Rash—Cisplatin—testicular cancer	0.000259	0.00125	CcSEcCtD
Trifluoperazine—Dermatitis—Cisplatin—testicular cancer	0.000259	0.00125	CcSEcCtD
Trifluoperazine—Erythema—Epirubicin—testicular cancer	0.000259	0.00124	CcSEcCtD
Trifluoperazine—Nervousness—Epirubicin—testicular cancer	0.000251	0.00121	CcSEcCtD
Trifluoperazine—Dizziness—Etoposide—testicular cancer	0.000249	0.0012	CcSEcCtD
Trifluoperazine—Muscle spasms—Epirubicin—testicular cancer	0.000249	0.0012	CcSEcCtD
Trifluoperazine—Leukopenia—Methotrexate—testicular cancer	0.000247	0.00119	CcSEcCtD
Trifluoperazine—Nausea—Cisplatin—testicular cancer	0.000244	0.00117	CcSEcCtD
Trifluoperazine—Vision blurred—Epirubicin—testicular cancer	0.000244	0.00117	CcSEcCtD
Trifluoperazine—Cough—Methotrexate—testicular cancer	0.000241	0.00116	CcSEcCtD
Trifluoperazine—Convulsion—Methotrexate—testicular cancer	0.000239	0.00115	CcSEcCtD
Trifluoperazine—Erythema—Doxorubicin—testicular cancer	0.000239	0.00115	CcSEcCtD
Trifluoperazine—Agitation—Epirubicin—testicular cancer	0.000238	0.00114	CcSEcCtD
Trifluoperazine—Rash—Etoposide—testicular cancer	0.000237	0.00114	CcSEcCtD
Trifluoperazine—Dermatitis—Etoposide—testicular cancer	0.000237	0.00114	CcSEcCtD
Trifluoperazine—Headache—Etoposide—testicular cancer	0.000236	0.00113	CcSEcCtD
Trifluoperazine—Nervousness—Doxorubicin—testicular cancer	0.000232	0.00112	CcSEcCtD
Trifluoperazine—Leukopenia—Epirubicin—testicular cancer	0.000231	0.00111	CcSEcCtD
Trifluoperazine—Muscle spasms—Doxorubicin—testicular cancer	0.00023	0.00111	CcSEcCtD
Trifluoperazine—Cough—Epirubicin—testicular cancer	0.000226	0.00109	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Methotrexate—testicular cancer	0.000226	0.00108	CcSEcCtD
Trifluoperazine—Vision blurred—Doxorubicin—testicular cancer	0.000225	0.00108	CcSEcCtD
Trifluoperazine—Convulsion—Epirubicin—testicular cancer	0.000224	0.00108	CcSEcCtD
Trifluoperazine—Nausea—Etoposide—testicular cancer	0.000224	0.00108	CcSEcCtD
Trifluoperazine—Agitation—Doxorubicin—testicular cancer	0.00022	0.00106	CcSEcCtD
Trifluoperazine—Skin disorder—Methotrexate—testicular cancer	0.000219	0.00105	CcSEcCtD
Trifluoperazine—Dry mouth—Epirubicin—testicular cancer	0.000215	0.00104	CcSEcCtD
Trifluoperazine—Anorexia—Methotrexate—testicular cancer	0.000215	0.00103	CcSEcCtD
Trifluoperazine—Leukopenia—Doxorubicin—testicular cancer	0.000214	0.00103	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Epirubicin—testicular cancer	0.000211	0.00102	CcSEcCtD
Trifluoperazine—Hypotension—Methotrexate—testicular cancer	0.000211	0.00101	CcSEcCtD
Trifluoperazine—Cough—Doxorubicin—testicular cancer	0.000209	0.001	CcSEcCtD
Trifluoperazine—Convulsion—Doxorubicin—testicular cancer	0.000207	0.000997	CcSEcCtD
Trifluoperazine—Skin disorder—Epirubicin—testicular cancer	0.000205	0.000986	CcSEcCtD
Trifluoperazine—Insomnia—Methotrexate—testicular cancer	0.000204	0.000981	CcSEcCtD
Trifluoperazine—Anorexia—Epirubicin—testicular cancer	0.000201	0.000968	CcSEcCtD
Trifluoperazine—Dyspnoea—Methotrexate—testicular cancer	0.000201	0.000967	CcSEcCtD
Trifluoperazine—Somnolence—Methotrexate—testicular cancer	0.0002	0.000964	CcSEcCtD
Trifluoperazine—Dry mouth—Doxorubicin—testicular cancer	0.000199	0.000958	CcSEcCtD
Trifluoperazine—Hypotension—Epirubicin—testicular cancer	0.000197	0.000949	CcSEcCtD
Trifluoperazine—Decreased appetite—Methotrexate—testicular cancer	0.000196	0.000943	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Doxorubicin—testicular cancer	0.000195	0.000939	CcSEcCtD
Trifluoperazine—Fatigue—Methotrexate—testicular cancer	0.000194	0.000935	CcSEcCtD
Trifluoperazine—Insomnia—Epirubicin—testicular cancer	0.000191	0.000918	CcSEcCtD
Trifluoperazine—Skin disorder—Doxorubicin—testicular cancer	0.00019	0.000912	CcSEcCtD
Trifluoperazine—Dyspnoea—Epirubicin—testicular cancer	0.000188	0.000905	CcSEcCtD
Trifluoperazine—Somnolence—Epirubicin—testicular cancer	0.000188	0.000902	CcSEcCtD
Trifluoperazine—Anorexia—Doxorubicin—testicular cancer	0.000186	0.000895	CcSEcCtD
Trifluoperazine—Decreased appetite—Epirubicin—testicular cancer	0.000183	0.000882	CcSEcCtD
Trifluoperazine—Hypotension—Doxorubicin—testicular cancer	0.000182	0.000878	CcSEcCtD
Trifluoperazine—Fatigue—Epirubicin—testicular cancer	0.000182	0.000875	CcSEcCtD
Trifluoperazine—Constipation—Epirubicin—testicular cancer	0.00018	0.000868	CcSEcCtD
Trifluoperazine—Urticaria—Methotrexate—testicular cancer	0.000179	0.000862	CcSEcCtD
Trifluoperazine—Body temperature increased—Methotrexate—testicular cancer	0.000178	0.000857	CcSEcCtD
Trifluoperazine—Insomnia—Doxorubicin—testicular cancer	0.000177	0.00085	CcSEcCtD
Trifluoperazine—Dyspnoea—Doxorubicin—testicular cancer	0.000174	0.000837	CcSEcCtD
Trifluoperazine—Somnolence—Doxorubicin—testicular cancer	0.000174	0.000835	CcSEcCtD
Trifluoperazine—Decreased appetite—Doxorubicin—testicular cancer	0.00017	0.000816	CcSEcCtD
Trifluoperazine—Fatigue—Doxorubicin—testicular cancer	0.000168	0.00081	CcSEcCtD
Trifluoperazine—Urticaria—Epirubicin—testicular cancer	0.000168	0.000806	CcSEcCtD
Trifluoperazine—Constipation—Doxorubicin—testicular cancer	0.000167	0.000803	CcSEcCtD
Trifluoperazine—Body temperature increased—Epirubicin—testicular cancer	0.000167	0.000802	CcSEcCtD
Trifluoperazine—Hypersensitivity—Methotrexate—testicular cancer	0.000166	0.000799	CcSEcCtD
Trifluoperazine—Asthenia—Methotrexate—testicular cancer	0.000162	0.000778	CcSEcCtD
Trifluoperazine—Pruritus—Methotrexate—testicular cancer	0.00016	0.000767	CcSEcCtD
Trifluoperazine—Hypersensitivity—Epirubicin—testicular cancer	0.000155	0.000748	CcSEcCtD
Trifluoperazine—Urticaria—Doxorubicin—testicular cancer	0.000155	0.000746	CcSEcCtD
Trifluoperazine—Body temperature increased—Doxorubicin—testicular cancer	0.000154	0.000742	CcSEcCtD
Trifluoperazine—Asthenia—Epirubicin—testicular cancer	0.000151	0.000728	CcSEcCtD
Trifluoperazine—Pruritus—Epirubicin—testicular cancer	0.000149	0.000718	CcSEcCtD
Trifluoperazine—Dizziness—Methotrexate—testicular cancer	0.000149	0.000717	CcSEcCtD
Trifluoperazine—Hypersensitivity—Doxorubicin—testicular cancer	0.000144	0.000692	CcSEcCtD
Trifluoperazine—Rash—Methotrexate—testicular cancer	0.000142	0.000684	CcSEcCtD
Trifluoperazine—Dermatitis—Methotrexate—testicular cancer	0.000142	0.000683	CcSEcCtD
Trifluoperazine—Headache—Methotrexate—testicular cancer	0.000141	0.00068	CcSEcCtD
Trifluoperazine—Asthenia—Doxorubicin—testicular cancer	0.00014	0.000674	CcSEcCtD
Trifluoperazine—Dizziness—Epirubicin—testicular cancer	0.00014	0.000671	CcSEcCtD
Trifluoperazine—Pruritus—Doxorubicin—testicular cancer	0.000138	0.000665	CcSEcCtD
Trifluoperazine—Nausea—Methotrexate—testicular cancer	0.000134	0.000644	CcSEcCtD
Trifluoperazine—Rash—Epirubicin—testicular cancer	0.000133	0.00064	CcSEcCtD
Trifluoperazine—Dermatitis—Epirubicin—testicular cancer	0.000133	0.000639	CcSEcCtD
Trifluoperazine—Headache—Epirubicin—testicular cancer	0.000132	0.000636	CcSEcCtD
Trifluoperazine—Dizziness—Doxorubicin—testicular cancer	0.000129	0.000621	CcSEcCtD
Trifluoperazine—Nausea—Epirubicin—testicular cancer	0.000125	0.000603	CcSEcCtD
Trifluoperazine—Rash—Doxorubicin—testicular cancer	0.000123	0.000592	CcSEcCtD
Trifluoperazine—Dermatitis—Doxorubicin—testicular cancer	0.000123	0.000592	CcSEcCtD
Trifluoperazine—Headache—Doxorubicin—testicular cancer	0.000122	0.000588	CcSEcCtD
Trifluoperazine—Nausea—Doxorubicin—testicular cancer	0.000116	0.000558	CcSEcCtD
Trifluoperazine—CALM3—Signaling by EGFR in Cancer—KITLG—testicular cancer	2.87e-05	0.00343	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by PDGF—KITLG—testicular cancer	2.86e-05	0.00341	CbGpPWpGaD
Trifluoperazine—CALM2—DAP12 interactions—KITLG—testicular cancer	2.83e-05	0.00338	CbGpPWpGaD
Trifluoperazine—CALM2—Fc epsilon receptor (FCERI) signaling—KITLG—testicular cancer	2.83e-05	0.00338	CbGpPWpGaD
Trifluoperazine—CALM1—DAP12 interactions—KITLG—testicular cancer	2.83e-05	0.00338	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by FGFR in disease—KITLG—testicular cancer	2.83e-05	0.00338	CbGpPWpGaD
Trifluoperazine—CALM1—Fc epsilon receptor (FCERI) signaling—KITLG—testicular cancer	2.83e-05	0.00338	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by FGFR in disease—KITLG—testicular cancer	2.83e-05	0.00338	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by EGFR—KITLG—testicular cancer	2.8e-05	0.00335	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by EGFR—KITLG—testicular cancer	2.8e-05	0.00335	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by EGFR in Cancer—KITLG—testicular cancer	2.78e-05	0.00332	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by EGFR in Cancer—KITLG—testicular cancer	2.78e-05	0.00332	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by PDGF—KITLG—testicular cancer	2.76e-05	0.0033	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by PDGF—KITLG—testicular cancer	2.76e-05	0.0033	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—INSL3—testicular cancer	2.73e-05	0.00327	CbGpPWpGaD
Trifluoperazine—CALM3—B Cell Activation—KITLG—testicular cancer	2.7e-05	0.00323	CbGpPWpGaD
Trifluoperazine—CYP1A2—Biological oxidations—HPGDS—testicular cancer	2.69e-05	0.00321	CbGpPWpGaD
Trifluoperazine—CALM1—B Cell Activation—KITLG—testicular cancer	2.62e-05	0.00312	CbGpPWpGaD
Trifluoperazine—CALM2—B Cell Activation—KITLG—testicular cancer	2.62e-05	0.00312	CbGpPWpGaD
Trifluoperazine—CALM3—RNF mutants show enhanced WNT signaling and proliferation—H2AFZ—testicular cancer	2.6e-05	0.00311	CbGpPWpGaD
Trifluoperazine—CALM3—NGF signalling via TRKA from the plasma membrane—KITLG—testicular cancer	2.59e-05	0.00309	CbGpPWpGaD
Trifluoperazine—CALM2—RNF mutants show enhanced WNT signaling and proliferation—H2AFZ—testicular cancer	2.52e-05	0.00301	CbGpPWpGaD
Trifluoperazine—CALM1—RNF mutants show enhanced WNT signaling and proliferation—H2AFZ—testicular cancer	2.52e-05	0.00301	CbGpPWpGaD
Trifluoperazine—CALM2—NGF signalling via TRKA from the plasma membrane—KITLG—testicular cancer	2.5e-05	0.00299	CbGpPWpGaD
Trifluoperazine—CALM1—NGF signalling via TRKA from the plasma membrane—KITLG—testicular cancer	2.5e-05	0.00299	CbGpPWpGaD
Trifluoperazine—CALM3—Downstream signaling of activated FGFR—FGFR3—testicular cancer	2.49e-05	0.00298	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by GPCR—INSL3—testicular cancer	2.46e-05	0.00293	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by WNT in cancer—H2AFZ—testicular cancer	2.42e-05	0.00289	CbGpPWpGaD
Trifluoperazine—CALM2—Downstream signaling of activated FGFR—FGFR3—testicular cancer	2.41e-05	0.00288	CbGpPWpGaD
Trifluoperazine—CALM1—Downstream signaling of activated FGFR—FGFR3—testicular cancer	2.41e-05	0.00288	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by GPCR—INSL3—testicular cancer	2.38e-05	0.00284	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by GPCR—INSL3—testicular cancer	2.38e-05	0.00284	CbGpPWpGaD
Trifluoperazine—CALM3—Downstream signal transduction—FGFR3—testicular cancer	2.34e-05	0.0028	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by WNT in cancer—H2AFZ—testicular cancer	2.34e-05	0.00279	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by WNT in cancer—H2AFZ—testicular cancer	2.34e-05	0.00279	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by FGFR—FGFR3—testicular cancer	2.33e-05	0.00278	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by ERBB2—FGFR3—testicular cancer	2.32e-05	0.00277	CbGpPWpGaD
Trifluoperazine—CALM3—DAP12 signaling—FGFR3—testicular cancer	2.31e-05	0.00276	CbGpPWpGaD
Trifluoperazine—CALM3—Downstream signaling of activated FGFR—KIT—testicular cancer	2.29e-05	0.00273	CbGpPWpGaD
Trifluoperazine—CALM1—Downstream signal transduction—FGFR3—testicular cancer	2.27e-05	0.00271	CbGpPWpGaD
Trifluoperazine—CALM2—Downstream signal transduction—FGFR3—testicular cancer	2.27e-05	0.00271	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by FGFR—FGFR3—testicular cancer	2.25e-05	0.00269	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by FGFR—FGFR3—testicular cancer	2.25e-05	0.00269	CbGpPWpGaD
Trifluoperazine—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	2.25e-05	0.00269	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by ERBB2—FGFR3—testicular cancer	2.24e-05	0.00268	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by ERBB2—FGFR3—testicular cancer	2.24e-05	0.00268	CbGpPWpGaD
Trifluoperazine—CALM1—DAP12 signaling—FGFR3—testicular cancer	2.23e-05	0.00267	CbGpPWpGaD
Trifluoperazine—CALM2—DAP12 signaling—FGFR3—testicular cancer	2.23e-05	0.00267	CbGpPWpGaD
Trifluoperazine—CALM2—Downstream signaling of activated FGFR—KIT—testicular cancer	2.21e-05	0.00264	CbGpPWpGaD
Trifluoperazine—CALM1—Downstream signaling of activated FGFR—KIT—testicular cancer	2.21e-05	0.00264	CbGpPWpGaD
Trifluoperazine—XDH—Metabolism—HPGDS—testicular cancer	2.19e-05	0.00261	CbGpPWpGaD
Trifluoperazine—UGT1A4—Metabolism—HPGDS—testicular cancer	2.19e-05	0.00261	CbGpPWpGaD
Trifluoperazine—CALM3—DAP12 interactions—FGFR3—testicular cancer	2.17e-05	0.00259	CbGpPWpGaD
Trifluoperazine—CALM3—Fc epsilon receptor (FCERI) signaling—FGFR3—testicular cancer	2.17e-05	0.00259	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by FGFR in disease—FGFR3—testicular cancer	2.17e-05	0.00259	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by EGFR—FGFR3—testicular cancer	2.15e-05	0.00257	CbGpPWpGaD
Trifluoperazine—CALM3—Downstream signal transduction—KIT—testicular cancer	2.15e-05	0.00257	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by FGFR—KIT—testicular cancer	2.14e-05	0.00256	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by EGFR in Cancer—FGFR3—testicular cancer	2.13e-05	0.00255	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by ERBB2—KIT—testicular cancer	2.13e-05	0.00254	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by PDGF—FGFR3—testicular cancer	2.12e-05	0.00254	CbGpPWpGaD
Trifluoperazine—CALM3—DAP12 signaling—KIT—testicular cancer	2.12e-05	0.00253	CbGpPWpGaD
Trifluoperazine—CALM2—Fc epsilon receptor (FCERI) signaling—FGFR3—testicular cancer	2.1e-05	0.00251	CbGpPWpGaD
Trifluoperazine—CALM1—Fc epsilon receptor (FCERI) signaling—FGFR3—testicular cancer	2.1e-05	0.00251	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by FGFR in disease—FGFR3—testicular cancer	2.1e-05	0.00251	CbGpPWpGaD
Trifluoperazine—CALM2—DAP12 interactions—FGFR3—testicular cancer	2.1e-05	0.00251	CbGpPWpGaD
Trifluoperazine—CALM1—DAP12 interactions—FGFR3—testicular cancer	2.1e-05	0.00251	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by FGFR in disease—FGFR3—testicular cancer	2.1e-05	0.00251	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by EGFR—FGFR3—testicular cancer	2.08e-05	0.00249	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by EGFR—FGFR3—testicular cancer	2.08e-05	0.00249	CbGpPWpGaD
Trifluoperazine—CALM2—Downstream signal transduction—KIT—testicular cancer	2.08e-05	0.00248	CbGpPWpGaD
Trifluoperazine—CALM1—Downstream signal transduction—KIT—testicular cancer	2.08e-05	0.00248	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by FGFR—KIT—testicular cancer	2.07e-05	0.00247	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by FGFR—KIT—testicular cancer	2.07e-05	0.00247	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by EGFR in Cancer—FGFR3—testicular cancer	2.06e-05	0.00246	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by EGFR in Cancer—FGFR3—testicular cancer	2.06e-05	0.00246	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by ERBB2—KIT—testicular cancer	2.06e-05	0.00246	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by ERBB2—KIT—testicular cancer	2.06e-05	0.00246	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by PDGF—FGFR3—testicular cancer	2.05e-05	0.00245	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by PDGF—FGFR3—testicular cancer	2.05e-05	0.00245	CbGpPWpGaD
Trifluoperazine—CALM2—DAP12 signaling—KIT—testicular cancer	2.05e-05	0.00245	CbGpPWpGaD
Trifluoperazine—CALM1—DAP12 signaling—KIT—testicular cancer	2.05e-05	0.00245	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—INSL3—testicular cancer	2.02e-05	0.00242	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—INSL3—testicular cancer	2.01e-05	0.00241	CbGpPWpGaD
Trifluoperazine—CALM3—B Cell Activation—FGFR3—testicular cancer	2.01e-05	0.0024	CbGpPWpGaD
Trifluoperazine—CALM3—DAP12 interactions—KIT—testicular cancer	1.99e-05	0.00238	CbGpPWpGaD
Trifluoperazine—CALM3—Fc epsilon receptor (FCERI) signaling—KIT—testicular cancer	1.99e-05	0.00238	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by FGFR in disease—KIT—testicular cancer	1.99e-05	0.00238	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by Wnt—H2AFZ—testicular cancer	1.99e-05	0.00238	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by NGF—KITLG—testicular cancer	1.99e-05	0.00238	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by EGFR—KIT—testicular cancer	1.98e-05	0.00236	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by EGFR in Cancer—KIT—testicular cancer	1.96e-05	0.00234	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by PDGF—KIT—testicular cancer	1.95e-05	0.00233	CbGpPWpGaD
Trifluoperazine—CALM1—B Cell Activation—FGFR3—testicular cancer	1.94e-05	0.00232	CbGpPWpGaD
Trifluoperazine—CALM2—B Cell Activation—FGFR3—testicular cancer	1.94e-05	0.00232	CbGpPWpGaD
Trifluoperazine—CALM1—DAP12 interactions—KIT—testicular cancer	1.93e-05	0.0023	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by FGFR in disease—KIT—testicular cancer	1.93e-05	0.0023	CbGpPWpGaD
Trifluoperazine—CALM2—DAP12 interactions—KIT—testicular cancer	1.93e-05	0.0023	CbGpPWpGaD
Trifluoperazine—CALM1—Fc epsilon receptor (FCERI) signaling—KIT—testicular cancer	1.93e-05	0.0023	CbGpPWpGaD
Trifluoperazine—CALM2—Fc epsilon receptor (FCERI) signaling—KIT—testicular cancer	1.93e-05	0.0023	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by FGFR in disease—KIT—testicular cancer	1.93e-05	0.0023	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by Wnt—H2AFZ—testicular cancer	1.93e-05	0.0023	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by Wnt—H2AFZ—testicular cancer	1.93e-05	0.0023	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by NGF—KITLG—testicular cancer	1.93e-05	0.0023	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by NGF—KITLG—testicular cancer	1.93e-05	0.0023	CbGpPWpGaD
Trifluoperazine—CALM3—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	1.92e-05	0.0023	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by EGFR—KIT—testicular cancer	1.91e-05	0.00228	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by EGFR—KIT—testicular cancer	1.91e-05	0.00228	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by EGFR in Cancer—KIT—testicular cancer	1.89e-05	0.00226	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by EGFR in Cancer—KIT—testicular cancer	1.89e-05	0.00226	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by PDGF—KIT—testicular cancer	1.89e-05	0.00225	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by PDGF—KIT—testicular cancer	1.89e-05	0.00225	CbGpPWpGaD
Trifluoperazine—CALM3—Innate Immune System—BCL10—testicular cancer	1.88e-05	0.00225	CbGpPWpGaD
Trifluoperazine—CALM2—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	1.86e-05	0.00222	CbGpPWpGaD
Trifluoperazine—CALM1—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	1.86e-05	0.00222	CbGpPWpGaD
Trifluoperazine—CALM3—B Cell Activation—KIT—testicular cancer	1.84e-05	0.0022	CbGpPWpGaD
Trifluoperazine—CALM1—Innate Immune System—BCL10—testicular cancer	1.82e-05	0.00218	CbGpPWpGaD
Trifluoperazine—CALM2—Innate Immune System—BCL10—testicular cancer	1.82e-05	0.00218	CbGpPWpGaD
Trifluoperazine—CALM3—Adaptive Immune System—BCL10—testicular cancer	1.81e-05	0.00216	CbGpPWpGaD
Trifluoperazine—CALM1—B Cell Activation—KIT—testicular cancer	1.78e-05	0.00213	CbGpPWpGaD
Trifluoperazine—CALM2—B Cell Activation—KIT—testicular cancer	1.78e-05	0.00213	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—INSL3—testicular cancer	1.78e-05	0.00212	CbGpPWpGaD
Trifluoperazine—CALM3—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	1.77e-05	0.00211	CbGpPWpGaD
Trifluoperazine—CALM2—Adaptive Immune System—BCL10—testicular cancer	1.75e-05	0.00209	CbGpPWpGaD
Trifluoperazine—CALM1—Adaptive Immune System—BCL10—testicular cancer	1.75e-05	0.00209	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—INSL3—testicular cancer	1.75e-05	0.00209	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—INSL3—testicular cancer	1.74e-05	0.00208	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—INSL3—testicular cancer	1.72e-05	0.00205	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—INSL3—testicular cancer	1.71e-05	0.00205	CbGpPWpGaD
Trifluoperazine—CALM2—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	1.71e-05	0.00204	CbGpPWpGaD
Trifluoperazine—CALM1—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	1.71e-05	0.00204	CbGpPWpGaD
Trifluoperazine—UGT1A4—Metabolism—STK11—testicular cancer	1.59e-05	0.0019	CbGpPWpGaD
Trifluoperazine—XDH—Metabolism—STK11—testicular cancer	1.59e-05	0.0019	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by NGF—FGFR3—testicular cancer	1.48e-05	0.00177	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—INSL3—testicular cancer	1.45e-05	0.00173	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by NGF—FGFR3—testicular cancer	1.43e-05	0.00171	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by NGF—FGFR3—testicular cancer	1.43e-05	0.00171	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—INSL3—testicular cancer	1.4e-05	0.00168	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—INSL3—testicular cancer	1.4e-05	0.00168	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by NGF—KIT—testicular cancer	1.36e-05	0.00162	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by NGF—KIT—testicular cancer	1.31e-05	0.00157	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by NGF—KIT—testicular cancer	1.31e-05	0.00157	CbGpPWpGaD
Trifluoperazine—CALM3—Innate Immune System—KITLG—testicular cancer	1.14e-05	0.00136	CbGpPWpGaD
Trifluoperazine—CALM2—Innate Immune System—KITLG—testicular cancer	1.1e-05	0.00131	CbGpPWpGaD
Trifluoperazine—CALM1—Innate Immune System—KITLG—testicular cancer	1.1e-05	0.00131	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—BCL10—testicular cancer	1.1e-05	0.00131	CbGpPWpGaD
Trifluoperazine—CALM3—Adaptive Immune System—KITLG—testicular cancer	1.09e-05	0.0013	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—BCL10—testicular cancer	1.06e-05	0.00127	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—BCL10—testicular cancer	1.06e-05	0.00127	CbGpPWpGaD
Trifluoperazine—CALM2—Adaptive Immune System—KITLG—testicular cancer	1.05e-05	0.00126	CbGpPWpGaD
Trifluoperazine—CALM1—Adaptive Immune System—KITLG—testicular cancer	1.05e-05	0.00126	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	1.03e-05	0.00123	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—H2AFZ—testicular cancer	8.75e-06	0.00105	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—STK11—testicular cancer	8.7e-06	0.00104	CbGpPWpGaD
Trifluoperazine—CALM3—Innate Immune System—FGFR3—testicular cancer	8.44e-06	0.00101	CbGpPWpGaD
Trifluoperazine—CALM2—Innate Immune System—FGFR3—testicular cancer	8.16e-06	0.000975	CbGpPWpGaD
Trifluoperazine—CALM1—Innate Immune System—FGFR3—testicular cancer	8.16e-06	0.000975	CbGpPWpGaD
Trifluoperazine—CALM3—Adaptive Immune System—FGFR3—testicular cancer	8.1e-06	0.000968	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—KITLG—testicular cancer	8.05e-06	0.000962	CbGpPWpGaD
Trifluoperazine—CALM2—Adaptive Immune System—FGFR3—testicular cancer	7.84e-06	0.000936	CbGpPWpGaD
Trifluoperazine—CALM1—Adaptive Immune System—FGFR3—testicular cancer	7.84e-06	0.000936	CbGpPWpGaD
Trifluoperazine—CALM3—Innate Immune System—KIT—testicular cancer	7.75e-06	0.000925	CbGpPWpGaD
Trifluoperazine—CALM3—Metabolism—HPGDS—testicular cancer	7.6e-06	0.000908	CbGpPWpGaD
Trifluoperazine—CALM2—Innate Immune System—KIT—testicular cancer	7.49e-06	0.000895	CbGpPWpGaD
Trifluoperazine—CALM1—Innate Immune System—KIT—testicular cancer	7.49e-06	0.000895	CbGpPWpGaD
Trifluoperazine—CALM3—Adaptive Immune System—KIT—testicular cancer	7.44e-06	0.000888	CbGpPWpGaD
Trifluoperazine—CALM1—Metabolism—HPGDS—testicular cancer	7.36e-06	0.000879	CbGpPWpGaD
Trifluoperazine—CALM2—Metabolism—HPGDS—testicular cancer	7.36e-06	0.000879	CbGpPWpGaD
Trifluoperazine—CALM2—Adaptive Immune System—KIT—testicular cancer	7.2e-06	0.000859	CbGpPWpGaD
Trifluoperazine—CALM1—Adaptive Immune System—KIT—testicular cancer	7.2e-06	0.000859	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—H2AFZ—testicular cancer	6.64e-06	0.000793	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—KITLG—testicular cancer	6.61e-06	0.00079	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—H2AFZ—testicular cancer	6.48e-06	0.000774	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—H2AFZ—testicular cancer	6.45e-06	0.00077	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—STK11—testicular cancer	6.44e-06	0.000769	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—H2AFZ—testicular cancer	6.42e-06	0.000767	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—H2AFZ—testicular cancer	6.42e-06	0.000767	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—STK11—testicular cancer	6.41e-06	0.000765	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—KITLG—testicular cancer	6.4e-06	0.000764	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—KITLG—testicular cancer	6.4e-06	0.000764	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—KITLG—testicular cancer	6.1e-06	0.000729	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—FGFR3—testicular cancer	5.98e-06	0.000715	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—KITLG—testicular cancer	5.96e-06	0.000712	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—KITLG—testicular cancer	5.93e-06	0.000708	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—KITLG—testicular cancer	5.9e-06	0.000705	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—KITLG—testicular cancer	5.9e-06	0.000705	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—HPGDS—testicular cancer	5.76e-06	0.000688	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—H2AFZ—testicular cancer	5.69e-06	0.000679	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—STK11—testicular cancer	5.66e-06	0.000676	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—H2AFZ—testicular cancer	5.6e-06	0.000669	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—H2AFZ—testicular cancer	5.59e-06	0.000667	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—STK11—testicular cancer	5.57e-06	0.000665	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—STK11—testicular cancer	5.55e-06	0.000663	CbGpPWpGaD
Trifluoperazine—CALM3—Metabolism—STK11—testicular cancer	5.52e-06	0.00066	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—H2AFZ—testicular cancer	5.5e-06	0.000656	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—KIT—testicular cancer	5.49e-06	0.000656	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—H2AFZ—testicular cancer	5.48e-06	0.000655	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—STK11—testicular cancer	5.46e-06	0.000653	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—STK11—testicular cancer	5.45e-06	0.000651	CbGpPWpGaD
Trifluoperazine—CALM2—Metabolism—STK11—testicular cancer	5.34e-06	0.000638	CbGpPWpGaD
Trifluoperazine—CALM1—Metabolism—STK11—testicular cancer	5.34e-06	0.000638	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—KITLG—testicular cancer	5.23e-06	0.000625	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—KITLG—testicular cancer	5.15e-06	0.000615	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—KITLG—testicular cancer	5.14e-06	0.000614	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—KITLG—testicular cancer	5.06e-06	0.000604	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—KITLG—testicular cancer	5.04e-06	0.000602	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—FGFR3—testicular cancer	4.91e-06	0.000587	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—FGFR3—testicular cancer	4.75e-06	0.000568	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—FGFR3—testicular cancer	4.75e-06	0.000568	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—H2AFZ—testicular cancer	4.65e-06	0.000555	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—STK11—testicular cancer	4.62e-06	0.000552	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—HPGDS—testicular cancer	4.6e-06	0.000549	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—FGFR3—testicular cancer	4.54e-06	0.000542	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—KIT—testicular cancer	4.51e-06	0.000539	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—H2AFZ—testicular cancer	4.49e-06	0.000537	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—H2AFZ—testicular cancer	4.49e-06	0.000537	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—STK11—testicular cancer	4.47e-06	0.000534	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—STK11—testicular cancer	4.47e-06	0.000534	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—FGFR3—testicular cancer	4.43e-06	0.000529	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—FGFR3—testicular cancer	4.41e-06	0.000526	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—FGFR3—testicular cancer	4.39e-06	0.000524	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—FGFR3—testicular cancer	4.39e-06	0.000524	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—KIT—testicular cancer	4.36e-06	0.000521	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—KIT—testicular cancer	4.36e-06	0.000521	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—KITLG—testicular cancer	4.27e-06	0.000511	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—STK11—testicular cancer	4.19e-06	0.0005	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—KIT—testicular cancer	4.17e-06	0.000498	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—KITLG—testicular cancer	4.14e-06	0.000494	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—KITLG—testicular cancer	4.14e-06	0.000494	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—KIT—testicular cancer	4.07e-06	0.000486	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—KIT—testicular cancer	4.05e-06	0.000483	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—KIT—testicular cancer	4.03e-06	0.000481	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—KIT—testicular cancer	4.03e-06	0.000481	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—FGFR3—testicular cancer	3.89e-06	0.000465	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—FGFR3—testicular cancer	3.83e-06	0.000457	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—FGFR3—testicular cancer	3.82e-06	0.000456	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—FGFR3—testicular cancer	3.76e-06	0.000449	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—FGFR3—testicular cancer	3.75e-06	0.000448	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—KIT—testicular cancer	3.57e-06	0.000427	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—KIT—testicular cancer	3.51e-06	0.00042	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—KIT—testicular cancer	3.51e-06	0.000419	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—KIT—testicular cancer	3.45e-06	0.000412	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—KIT—testicular cancer	3.44e-06	0.000411	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—STK11—testicular cancer	3.34e-06	0.000399	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—FGFR3—testicular cancer	3.18e-06	0.000379	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—FGFR3—testicular cancer	3.07e-06	0.000367	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—FGFR3—testicular cancer	3.07e-06	0.000367	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—KIT—testicular cancer	2.92e-06	0.000348	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—KIT—testicular cancer	2.82e-06	0.000337	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—KIT—testicular cancer	2.82e-06	0.000337	CbGpPWpGaD
